Off-target drug effect flips cell death, worsening TB in mice

Tuberculosis and related infections remain deadly partly because the way immune cells die during infection can help or hinder disease. Li Zhang and colleagues examined how certain bacterial infections change the fate of infected immune cells called macrophages, and how that influences disease in animals. The work focused on three organisms named in the study title—Mycobacterium tuberculosis, Mycobacterium kansasii and Rhodococcus equi—and on a cellular death pathway called necroptosis. In mice on the C57BL/6 background, which express high levels of type I IFN after Mtb infection and develop necrotic pulmonary lesions, the authors report that loss of the necroptosis executioner MLKL reduced bacterial burden and pathology after high-dose infection. The team also investigated the effects of a caspase-8 inhibitor and the related compound z-VAD in infected macrophages. Their findings point to a surprising twist: blocking one pathway with a drug can redirect cells into a different, more inflammatory kind of death, with consequences for tissue damage and bacterial control.

The central experimental observations described in the abstract are straightforward and specific. In macrophages infected with various Gram-positive pathogens, the authors show that a caspase-8 inhibitor had off-target action(s) that could switch the cell death pathway to necroptosis. The abstract calls out z-VAD as a compound that inhibited a non-canonical target or targets in these experiments. In the animal model work, the researchers used mice on the C57BL/6 background, a strain noted in this report for expressing high levels of type I IFN after Mtb infection and for developing necrotic pulmonary lesions under the study conditions. In those mice, MLKL-deficiency reduced bacterial burden and pathology after high-dose infection, implicating MLKL-driven necroptosis in worsening disease under these circumstances. Put together, the data presented indicate both a drug-related switching of macrophage death programs and a genetic link between MLKL and exacerbated tuberculosis in a susceptible mouse strain.

The findings have a few clear implications based on the abstract. First, tools commonly used to block caspases—such as the caspase-8 inhibitor and z-VAD—may have off-target effects that change how infected immune cells die, steering them into necroptosis rather than apoptosis. Second, MLKL-driven necroptosis can make tuberculosis worse in mice that are prone to necrotic lung lesions, suggesting that the balance of cell death pathways can shape infection outcomes. The authors raise the possibility that pathophysiologic circumstances in real infections might reproduce the same inhibition of the non-canonical target(s) that z-VAD hit in the lab, thereby enabling MLKL to exacerbate disease. These conclusions call for caution in interpreting experiments that use broad inhibitors and for attention to how drugs might unintentionally redirect cell death in infected tissues.